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Trypanosoma brucei gambiense group 1 is the major causative agent of the Gambian human African trypano-
somiasis (HAT). Accurate diagnosis of Gambian HAT is still challenged by lack of precise diagnostic methods,
low and fluctuating parasitemia, and generally poor services in the areas of endemicity. In this study, we
designed a rapid loop-mediated isothermal amplification (LAMP) test for T. b. gambiense based on the 3 end
of the T. b. gambiense-specific glycoprotein (TgsGP) gene. The test is specific and amplifies DNA from T. b.
gambiense isolates and clinical samples at 62°C within 40 min using a normal water bath. The analytical
sensitivity of the TgsGP LAMP was equivalent to 10 trypanosomes/ml using purified DNA and 1 trypano-
some/ml using supernatant prepared from boiled blood, while those of classical PCR tests ranged from 10 to
103 trypanosomes/ml. There was 100% agreement in the detection of the LAMP product by real-time gel
electrophoresis and the DNA-intercalating dye SYBR green I. The LAMP amplicons were unequivocally
confirmed through sequencing and analysis of melting curves. The assay was able to amplify parasite DNA
from native cerebrospinal fluid (CSF) and double-centrifuged supernatant prepared from boiled buffy coat and
bone marrow aspirate. The robustness, superior sensitivity, and ability to inspect results visually through color
change indicate the potential of TgsGP LAMP as a future point-of-care test.
Trypanosoma brucei gambiense is the causative agent of the
Gambian form of human African trypanosomiasis (HAT) in
sub-Saharan Africa and is responsible for over 90% of all HAT
cases (7). The Gambian HAT is endemic to rural areas of West
and Central Africa, where deterioration of control activities,
severe disruptions of health services, and population move-
ments into high-risk areas have led to resurgence of the disease
(47). T. b. gambiense infection is characterized by low para-
sitemia with no specific clinical symptoms (15), especially dur-
ing the early stage, when the trypanosomes are confined to the
hemolymphatic system. This has limited the use of standard
diagnostic techniques, with an estimated 20 to 30% of patients
being undiagnosed (42). The serological test—card agglutina-
tion test for trypanosomiasis (CATT)—for T. b. gambiense (24)
is widely used; however, the test has varying sensitivities (46)
and cannot decisively differentiate between active and cured
cases (19). On the molecular side, several PCR tests have been
developed (6, 30, 41), but issues of sensitivity and reproduc-
ibility (44) and the requirement for high-precision instrumen-
tation have limited their use.
Early and accurate diagnosis of Gambian HAT is essential,
since the drugs used for treatment, particularly those for the
late stage, can cause unacceptably severe side effects. The first
stage of disease is treated with pentamidine, while the second
stage is treated with melarsoprol, which is associated with
encephalopathy in about 10% of treated patients (39, 49).
Eflornithine is an alternative drug for the second stage of
Gambian HAT but is expensive and difficult to administer (48).
The latest advance in treatment has been a combination of
eflornithine and nifurtimox (40); this brings with it reduction of
the treatment duration, as well as the number of eflornithine
infusions, to the relief of nursing staff attending to the patients.
This complexity in the treatment regime calls for a diagnostic
test(s) that is accurate and that minimizes false positives to
reduce overtreatment and exposure of patients to expensive
and potentially toxic drugs whose efficacy may not be guaran-
teed.
In recent years, a DNA amplification platform called loop-
mediated isothermal amplification (LAMP) has been devel-
oped (36). The technique has been used to develop LAMP
tests specific for the subgenus Trypanozoon (18, 34, 45) and
Trypanosoma brucei rhodesiense (35), but so far, there is no
LAMP test for T. b. gambiense. The major advantages of
LAMP include (i) rapidity and the use of six to eight primers
providing high specificity; (ii) ability of the technique to am-
plify target DNA from partially processed template; (iii) re-
quirement for only a simple heating device, such as a water
bath; and (iv) results that can be inspected visually through the
use of varied detection formats, such as turbidity (28), fluores-
cent dye (5), probes (1, 27), lateral-flow dipstick (LFD) format
(31), and microfluidic chips (13). LAMP has attracted much
interest as an easily applicable yet highly sensitive molecular
tool with great potential for diagnosis in resource-poor rural
settings, where HAT typically occurs. This is demonstrated by
the large number of publications on the technique (26).
The molecular characterization of human-infective trypano-
somes indicates that the majority of Gambian HAT cases are
caused by a genetically homogeneous group, group 1 T. b.
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gambiense (12, 17, 37), with group 2 T. b. gambiense accounting
for an insignificant percentage (25). In addition, studies have
identified a T. b. gambiense-specific glycoprotein (TgsGP) gene
(2) that is specific to group 1 T. b. gambiense and absent in
isolates from group 2 (14). The 3 end of the TgsGP gene has
been used to develop the only reliable PCR tests for T. b.
gambiense (41). In this study, we designed a rapid and sensitive
LAMP test based on the 3 end of the TgsGP gene and eval-
uated it using Trypanozoon isolates and clinical samples from
HAT patients with a view to obtaining data for a more com-
prehensive field study.
MATERIALS AND METHODS
Ethical clearance. Institutional ethical clearance for the collection of human
samples in Uganda was obtained from the Uganda National Council of Science
and Technology (UNCST), Kampala, Uganda, as reported previously (34), and
the use of samples from a HAT patient diagnosed in Australia was approved by
Royal Perth Hospital, Western Australia, Australia, through Christopher Heath.
Reference DNA. Well-characterized T. b. gambiense DNA samples were used
in this study, as shown in Table 1. The DNA was prepared either using a Qiagen
DNA extraction kit (Qiagen, Victoria, Australia) or by the published method
(43). The samples were chosen to ensure wide geographical representation.
DNA from other trypanosome species, tsetse fly, bovine, human, and Plasmo-
dium falciparum were included to check the test specificity.
Clinical samples. Ten DNA samples prepared from blood and cerebrospinal
fluid (CSF) from confirmed T. b. gambiense patients in Uganda, as previously
reported (35), were used. The OM series samples were purified using a Gentra
(Minneapolis, MN) DNA purification kit. Additionally, a variety of samples (the
RPH series) from a T. b. gambiense patient diagnosed in Australia were also
included (Table 2). The samples were prepared as follows. First, the buffy coat
(BC) was prepared from a pool of 10 heparinized blood capillaries and made up
to 210 l with ultrapure-grade water; then, equal amounts (210 l) of the BC, the
bone marrow aspirate (BMA), and CSF were divided into three equal portions
for (i) direct use, (ii) extraction of DNA using the commercial kit, and (iii)
supernatant processing as described previously (34). To reduce the chances of
false positives (33), the collected supernatant was double centrifuged at 14,000
rpm for 5 min. The prepared samples were then stored at 80°C until they were
needed. The template for a 50-l reaction mixture was 4 to 5 l for supernatant
and 1 to 2 l for DNA, direct BC, BMA, or CSF samples (Table 2).
Design of LAMP primers. A total of five primer sets recognizing six distinct
sections of TgsGP (accession number AJ277951) were designed using Primer
Explorer version 3 software (http://primerexplorer.jp/lamp3.0.0/index.html).
They included forward and backward outer primers (F3 and B3) and forward and
backward inner primers (FIP and BIP) (Table 3). Additionally, two loop primers,
loop forward (LF) and loop backward (LB), were manually designed for each set.
The 3 end of the TgsGP gene was chosen for amplification because of its
reported specificity to T. b. gambiense (14, 41). Primer specificity was checked
with the basic local alignment search tool (BLAST) against human DNA and
other human-infectious pathogens. The primer sets were analyzed with “must-
detect samples,” i.e., T. b. gambiense isolates, and “must-not-detect samples,” i.e.,
T. b. rhodesiense, Trypanosoma brucei brucei, and Trypanosoma evansi (Table 1).
TABLE 1. Trypanosome isolates used in the study
Species/subspecies Identificationcodea Isolate origin
Yr of
isolation Original host
Resultb
RIME
LAMPc
TgsGP
PCR
TgsGP
LAMPd
T. b. gambiense MOS (Mbam), Cameroon 1974 Human   
T. b. gambiense B014 (Fontem), Cameroon 1988 Human   
T. b. gambiense Font I (Fontem), Cameroon 1993 Human   
T. b. gambiense PT16 Ivory Coast 1992 Human   
T. b. gambiense PT41 Ivory Coast 1992 Human   
T. b. gambiense Boula Bouenza, Congo 1989 Human   
T. b. gambiense NW2 Uganda 1992 Human   
T. b. gambiense NW5 Uganda 1992 Human   
T. b. gambiense Da 972 Daloa, Ivory Coast 1978 Human   
T. b. gambiense Mba Daloa, Ivory Coast 1978 Human   
T. b. gambiense JE16 Adjuman, Uganda 1992 Human   
T. b. gambiense JE17 Adjuman, Uganda 1992 Human   
T. b. gambiense KETRI 2565 Sudan 1982 Human   
T. b. brucei LUMP 266 Kiboko, Kenya 1969 G. pallidipes   
T. b. brucei B8/18 (Nsukka), Nigeria 1962 Pig   
T. b. brucei J10 Luangwa Valley, Zambia 1973 Hyena   
T. b. brucei TSW187/78E Ivory Coast 1978 Pig   
T. b. brucei Katerema Uganda 1990 Cow   
T. b. rhodesiense WB 58 Uganda Human   
T. b. rhodesiense 058 Luangwa Valley, Zambia 1974 Human   
T. b. rhodesiense UTRO 2509 Uganda Human   
T. b. rhodesiense KETRI 2492 Lambwe Valley, Kenya 1980 Tsetse fly   
T. b. rhodesiense KETRI 3639 Busia, Kenya 1999 Human   
T. b. rhodesiense TMRS 58 Mpanda, Tanzania 2006 Human   
T. b. rhodesiense Gambella II Ethiopia 1968 Human   
T. evansi SA17 Isiolo, Kenya 2003 Camel   
T. evansi KETRI 3093 Colombia, South America 1979 Horse   
T. congolense forest Cam 22 Mbetta, Cameroon 1984 Goat   
T. c. Kilifi WG5 Kenya 1980 Sheep   
T. simiae Ken 4 Keneba, The Gambia 1988 Fly   
T. simiae tsavo KETRI 1864 Kenya Fly   
Bovine, human, tsetse
fly, P. falciparum
NA Kenya 1998–2003   
a Isolate identification reported (33). NA, not applicable.
b , positive; , negative.
c Specific for subgenus Trypanozoon (29).
d This study.
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The sets of primers that passed these criteria were then analyzed using a 10-fold
serial dilution of T. b. gambiense DNA from isolate PT41 under the standard
LAMP conditions (36). The most sensitive primer set (Table 3) was then chosen
for further analysis.
LAMP reactions. To improve the sensitivity of TgsGP LAMP primers, four
reaction mixture components (magnesium sulfate, FIP/BIP primers, deoxynu-
cleoside triphosphates [dNTPs], and betaine) were subjected to rigorous opti-
mization using the modified Taguchi method, followed by regression analysis to
determine the concentration optima for each reaction mixture component (9).
Briefly the forward inner primer (FIP) and backward inner primer (BIP) con-
centrations were varied from 20 to 80 pmol, dNTPs (Promega, NSW, Australia)
from 1 to 4 mM, betaine (Sigma-Aldrich, St. Louis, MO) from 0.5 to 2.0 M, and
magnesium sulfate (New England BioLabs, MA) from 0 to 6 mM. The 1
ThermoPol reaction buffer contained 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10
mM (NH4)2SO4, 2 mM MgSO4, and 0.1% Triton X-100. The Bst DNA poly-
merase (large fragment; New England BioLabs, MA) was at 1 l (8 units), while
SYTO-9 fluorescent dye at 3.0 M (Molecular Probes, OR) was added for each
real-time reaction. The template was 1 ng of purified trypanosome DNA from
the T. b. gambiense isolate PT41. The LAMP reaction was performed for 30 to
60 min at 62°C using the Rotor Gene 6000 (Qiagen, Victoria, Australia), and
data were acquired on the HRM channel (460 to 510 nm), followed by inacti-
vation of the reaction at 80°C for 4 min. After the optimized conditions were
determined, they were compared with the standard LAMP conditions, followed
by trials using a normal water bath that maintained the temperature at 62 to
63°C. For comparison purposes, the mobile genetic element (RIME) LAMP (34)
specific for the subgenus Trypanozoon was carried out.
Detection and confirmation of LAMP products. The formation of LAMP
product was first monitored in real time through fluorescence of Syto-9 dye, after
which the product was divided into two equal portions of 10 l each. One
portion was analyzed using electrophoresis in 2.0% agarose gels stained with
SYBR safe DNA gel stain and the other by visual inspection after the addition
of a 1/10 dilution of SYBR green I. Two approaches were used to confirm that
the TgsGP LAMP test amplified the correct target, namely, (i) the acquisition of
melting curves using 1°C steps, with a hold of 30 s, from 62°C to 96°C and (ii)
TABLE 2. Results of the analysis of various clinical samples from HAT patients
Source Sampleidentifier Template Origin
Yr of
isolation
PCR test resultsi LAMP test resultsi
Species/subspecies
TBRa TgsGPb RIMEc TgsGPf
Blood OM55c DNA Northwest Uganda 2004     T. b. gambiense
Blood OM56c DNA Northwest Uganda 2004     T. b. gambiense
Blood OM66c DNA Northwest Uganda 2004     T. b. gambiense
Blood OM62c DNA Northwest Uganda 2004     T. b. gambiense
Blood OM51c DNA Northwest Uganda 2004     T. b. gambiense
Blood OM52c DNA Northwest Uganda 2004     T. b. gambiense
Blood RPH1d DNA Australia 2008     T. b. gambiense
Blood RPH2d Supernatantg Australia 2008     T. b. gambiense
BC RPH3d DNA Australia 2008     T. b. gambiense
BC RPH4d Supernatant Australia 2008     T. b. gambiense
BC RPHbc BC Australia 2008 ND
h ND   T. b. gambiense
BMA RPH5d DNA Australia 2008     T. b. gambiense
BMA RHP6d Supernatant Australia 2008     T. b. gambiense
BMA RHPbma BMA Australia 2008 ND ND   T. b. gambiense
CSF OM54c DNA Northwest Uganda 2004     T. b. gambiense
CSF OM64c,e Supernatant Northwest Uganda 2004 ND ND   T. b. gambiense
CSF OM64c,e DNA Northwest Uganda 2004     T. b. gambiense
CSF RPH7d DNA Australia 2008     T. b. gambiense
CSF RPH8d Supernatant Australia 2008 ND ND   T. b. gambiense
CSF RPH9d Native Australia 2008     T. b. gambiense
Blood JE2c DNA Tororo, Uganda 1991     T. b. rhodesiense
Blood TMRS10Bc Supernatant Tanzania 2007 ND    T. b. rhodesiense
CSF JE8c DNA Tororo, Uganda 2001     T. b. rhodesiense
CSF JE9c Supernatant Tororo, Uganda 2001     T. b. rhodesiense
Serum TMRS11Sc DNA Tanzania 2007 ND    T. b. rhodesiense
a Reference 29.
b Reference 41.
c Reference 34.
d Reference 33.
e DNA and supernatant were prepared from the same sample.
f This study.
g All supernatants were double centrifuged, and 4 l was used as a template.
h ND, not done.
i , positive; , negative.
TABLE 3. Nucleotide sequences of the optimized LAMP primers targeting the TgsGP gene
Primer name Sequence (5–3) Length(baes)
Amplicon
sizea
Target
sequence
TgsGP-F3 GTTCGGAGAGCTCAGACAG 19 150 TgsGP gene
TgsGP-B3 CCAACCGTTCCCAGTGTTG 19
TgsGP-FIP TTGCTCCTTATCGCCGCCAGGCAAGAGCACAAAACCACAG 40
TgsGP-BIP TGACGGGGACAACGGCTATCTATTTAACGCAGACACCGCC 40
TgsGP-LF CCGCCCTGATCCCGCCTG 18
TgsGP-LB GCAACTGCACAGGAACGGCG 20
a Length between F2 and B2c.
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through cloning of the uppermost single band into a Topo-TA vector, transfor-
mation in Escherichia coli, and sequencing. The resulting sequence was manually
compared with the expected target sequence.
Sensitivity of TgsGP LAMP and PCR. A 10-fold serial dilution of 100 ng of
T. b. gambiense isolate PT41 DNA was used. Second, DNA and supernatant were
prepared from archived mouse blood that had been mixed with T. b. gambiense.
Briefly, cultured T. b. gambiense parasites were mixed with mouse blood, ad-
justed to achieve approximately 1.0 106 trypanosomes/ml, and divided into two
portions. One portion was used for DNA extraction using the Qiagen kit, and the
other was boiled for supernatant as described previously (34). Tenfold serial
dilutions were then prepared from the two DNA stocks, and the supernatant was
used to determine the analytical sensitivity of TgsGP LAMP, TgsGP PCR (41),
and nested TgsGP PCR (30). The LAMP test was carried out under optimized
conditions, and the PCR tests followed the respective published procedures. The
resulting LAMP and PCR products were electrophoresed in a 2.0% Tris-acetate-
EDTA (TAE) agarose gel stained with SYBR safe DNA gel stain (Invitrogen,
Victoria, Australia). The gel images were documented using the Gel-Doc-XR
system (Bio-Rad Laboratories).
RESULTS
Optimum conditions for TgsGP LAMP. The TgsGP primers
chosen (Table 3) target a 220-bp section of TgsGP sequence
that is between the specific sections amplified by the TgsGP
PCR test (41). Surprisingly, 3 of the 5 LAMP primer sets
amplified T. b. brucei isolates B8/18 from Nigeria and TSW187/
78E from Ivory Coast, raising the question of the specificity of
the T. b. gambiense 3 end. A fourth primer set had a detection
limit of 103 trypanosomes/ml, while the TgsGP primer set for
this study showed a detection limit of 102 trypanosomes/ml
using the 10-fold serial dilution of isolate PT41. The Taguchi
method determined the final/optimal FIP and BIP primer con-
centrations at 40 pmol of each, 3 mM for each deoxynucleoside
triphosphate, 1.2 M betaine, and 4 mM extra magnesium sul-
fate. The concentrations of other reagents were as previously
reported (36). The optimum temperature for TgsGP LAMP
was determined to be 62°C, and 35 min was the assay cutoff
point.
TgsGP-LAMP product. Positive LAMP reactions showed
exponential amplification curves, as visualized in the real-time
PCR machine. The advantage of optimization was demon-
strated by the reduction in the cycle threshold (CT) value by an
average of 5 cycles for all 10-fold serial dilutions (Fig. 1A) and
a 10-fold increase in sensitivity. T. b. gambiense isolates from
different geographical regions showed identical melting curves,
with a melting temperature (Tm) of 87°C (Fig. 1A), suggesting
amplicons with similar sequences. The positive LAMP prod-
ucts showed the predicted ladderlike pattern on the agarose
gel, indicating the formation of stem-loops with inverted re-
peats (Fig. 1B). Further addition of a 1/10 dilution of SYBR
green I showed a green color with positive reactions and or-
ange with negative reactions (Fig. 1C). Sequencing of the up-
permost LAMP band (Fig. 1B) revealed the predicted se-
quence from the F2-to-B2 primer region flanked by sequences
from regions F1 and B1c on the 3 and 5 ends (Fig. 2).
PCR and LAMP sensitivities. The PCR results are shown in
Tables 1 and 2. The positive samples showed the predicted
308-bp amplicon using TgsGP PCR and an 270-bp ampli-
con using nested TgsGP PCR. The analytical sensitivity was
equivalent to 103 trypanosomes/ml and 10 trypanosomes/ml for
the classical and nested TgsGP PCRs, respectively (Table 4).
The TgsGP LAMP showed a detection limit of approximately
10 trypanosomes/ml of 10-fold serial dilutions of T. b. gam-
biense PT41 and approximately 1 trypanosome/ml when super-
natant prepared from mouse blood was used (Table 4). The
TgsGP LAMP sensitivity results were identical when either a
Rotorgene 6000 thermocycler or a water bath was used as a
source of heat. The LAMP assay was specific, and no cross-
reactivity was recorded with nontarget DNA (Table 1).
Results for clinical samples. Results for various clinical sam-
ples from patients diagnosed with T. b. gambiense are shown in
Table 2. After eliminating the use of direct buffy coat (RPHbc)
and bone marrow aspirate (RPHbma) samples where inhibition
of the LAMP reaction was expected, the highly sensitive RIME
LAMP detected 12/18 samples and the TgsGP LAMP assay
detected 9/18 and 9/12 of the RIME LAMP-positive samples.
Analysis of various sample formats from single and different
patients using LAMP tests and Trypanozoon-specific PCR (29)
showed better results with BMA and CSF than with blood
(Table 2).
FIG. 1. (A) Amplification and postamplification melting curves ob-
tained with 1 ng of T. b. gambiense DNA isolate PT41 under optimized
(green line) and standard (blue line) LAMP conditions. The LAMP
reactions were more efficient when the optimized conditions were
used, with a reduction of an average of 5 cycles with every 10-fold serial
dilution. The standard and optimized conditions showed identical
melting curves, with a Tm of 87°C (arrow), indicating similar prod-
ucts. dF/dT, derivative of the fluorescence with respect to temperature.
(B) Electrophoresis of TgsGP LAMP products. Lane 1, T. b. brucei;
lane 2, T. b. rhodesiense; lane 3, T. evansi; lane 4, OM64 (DNA pre-
pared from CSF sample RPH9 [Table 2]); lane C, positive control (T.
b. gambiense PT41); lane NC, negative control. The arrow (x) indicates
the sequenced band. (C) Visual appearance of TgsGP LAMP ampli-
fication products after addition of 1/10 dilution of SYBR green I dye.
The dye fluoresces strongly when bound to the double-stranded DNA,
and the resulting DNA-dye complex gives a green color, while fluo-
rescence is minimal when the dye is free in the solution and gives an
orange/brown color. The reactions were carried out in water baths at
62 to 63°C for 40 min. 1, OM55; 2, OM51; 3, OM52; 4, RHP6; 5,
OM62; 6, OM54; 7, RHP9; 8, OM56; C, PT41; and NC, water.
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DISCUSSION
Case detection, followed by successful treatment, is a pre-
requisite for prevention and control of Gambian HAT. This
strategy has faced significant problems due to a lack of sensi-
tive diagnostic tests. Moreover, the diagnosis and staging of T.
b. gambiense disease remains challenging, because the clinical
features of the disease are not specific (4, 20). Therefore,
research into the advancement of HAT diagnostic capabilities
is still a priority. In this study, we have demonstrated specific
amplification of T. b. gambiense DNA using a LAMP assay
based on the TgsGP gene. The test is rapid, and amplification
is achieved within 30 min using a real-time PCR machine at
62°C (Fig. 1A) and 40 min using a normal water bath and
detecting the product through addition of fluorescent dye (Fig.
1C). Although the use of a normal water bath simplifies the
need for instrumentation, nevertheless, the requirement for
power to heat the water is still a drawback. As such, other
sources of heat, like packaged exothermic reactions, need to be
explored. The TgsGP LAMP was specific and exhibited ana-
lytical sensitivity of 10 trypanosomes/ml, which was equal to
that of nested TgsGP PCR (Table 4); therefore, to date,
TgsGP LAMP is the most sensitive single-step T. b. gambiense
DNA-based test. However, as was observed with the serum
resistance-associated (SRA) gene-based LAMP tests (35), this
specific laboratory-based sensitivity may not be reproducible
under field conditions, and thus, rigorous TgsGP LAMP field
evaluations will be the next most important step.
The potential usefulness of TgsGP LAMP as a point-of-care
test is demonstrated by the ability of the new assay to amplify
target DNA from various templates, such as native CSF and
double-centrifuged supernatant (Table 2). More promising is
the ability of TgsGP LAMP to achieve 10-fold-higher sensitiv-
ity from supernatant than from DNA prepared from the same
sample, meaning that DNA extraction may not be necessary,
which would also shorten the assay time. Similar results were
recorded with RIME LAMP (34). It is suggested that a signif-
icant amount of parasite DNA is lost during the extraction
process, resulting in a lower detection limit when purified
DNA is used as a template. However, before supernatant can
be relied upon as a template for LAMP reactions, protocols for
template purification and buffers that stabilize DNA in the
supernatant need to be developed. This is because false-posi-
tive results (albeit rare) have previously been recorded with
single centrifuged supernatants (33), while an initially positive
supernatant turns negative after 3 weeks of storage at 20°C,
suggesting degradation of the target DNA (Z. K. Njiru, un-
published data).
A field-based TgsGP LAMP will require a detection for-
mat(s) that is cheap and simple and that allows visual inspec-
tion of the results. However, most of these formats do not offer
the option of confirming the LAMP product. Therefore, it is
imperative to ensure that the developed test is specific and
amplifies the predicted target. False positives in LAMP reac-
tions are not necessarily absent and can result from amplicon
contamination, unprocessed templates, the quality and com-
position of primers (poorly designed primers, frequent freezing
and thawing, and AT-rich primers). In this study, the amplifi-
cation of the target sequence from purified DNA, supernatant,
and native CSF was unequivocally confirmed through postam-
plification acquisition of the melting curves, which showed a
consistent Tm of87°C (Fig. 1A), indicating similar sequences,
and through sequencing of the uppermost LAMP band (Fig.
1C), which showed the predicted target sequence (Fig. 2).
Therefore, the use of nonspecific dye in this study, supported
by both positive and negative controls, increases our confi-
dence.
FIG. 2. Representative sequence obtained after cloning and sequencing of the uppermost bands from the TgsGP LAMP product. The sequence
was identical to the expected target sequence of 195 bp (15 bp from F2 to B2, plus F1c, 20 bp, and B1, 22 bp). An identical sequence was obtained
for the LAMP product acquired using the native CSF sample RPH9 (Table 3). Shading is used to distinguish the primer sections. Note that the
sequence differs depending on the band sequenced and the inner primer initiating the reaction. F, forward primers; B, backward primers; L, loop
primers; C, complementary sequence.
TABLE 4. Analytical sensitivity of TgsGP LAMP assay compared with TgsGP PCR tests using templates from 10-fold serial dilution of
T. b. gambiense isolate PT41 and various templates prepared from mouse blood mixed with T. b. gambiense
Test Template Expectedspecificity
Result at 10-fold dilution ofc:
Reference
Neat 101 102 103 104 105 106 107 108
TgsGP LAMP Supernatanta T. b. gambiense          This study
TgsGP LAMP DNAb T. b. gambiense          This study
TgsGP (nested) DNA T. b. gambiense          (30)
TgsGP DNA T. b. gambiense          (41)
a Supernatant was prepared from mouse blood mixed with trypanosomes.
b DNA from T. b. gambiense PT41 and from mouse blood prepared from 1.0  106 trypanosomes/ml.
c 101, 1.0  105 trypanosomes/ml; 102, 1.0  104 trypanosomes/ml; 108, 0.01 trypanosomes/ml; neat, approximately 100 ng; , positive; , negative.
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Early and accurate diagnosis of T. b. gambiense is essential in
reducing the risk of progression of infection to the late stage,
which is difficult and dangerous to treat compared to the early
stage (22). The challenge of T. b. gambiense diagnosis is well
demonstrated in this study by low detection of parasite DNA in
the most used patient sample, blood (samples OM and RPH1
to -4), using the available DNA detection tests. TgsGP LAMP
detected 75% of the RIME LAMP-positive samples (Table 2).
The sensitivity of the RIME LAMP is expected to be higher,
since the test is a based on a multicopy gene (500 copies per
haploid genome) (3) while TgsGP is based on a low-copy-
number target. Unfortunately, RIME LAMP cannot differen-
tiate between T. b. gambiense and T. b. rhodesiense, which is
crucial, since the two parasites have different treatment regi-
mens. Moreover, in East Africa, the introduction of T. b. rho-
desiense into the T. b. gambiense region is certain to occur due
to the closeness of the two disease foci and the continuous
movement of livestock. We initially designed a test specific for
T. b. rhodesiense (36), and the TgsGP LAMP designed in this
study has the potential to contribute to T. b. gambiense diag-
nosis.
Our results show that the CSF is a better source of template
for diagnosis of stage II diseases than blood. This is supported
by the analysis of varied samples (native, supernatant, and
DNA) from different patients (Table 2). Similar superior de-
tection has been recorded using CSF PCR (16). Since the
presence of T. b. gambiense had been confirmed in all the
patients (34), it is suggested that the levels of parasitemia in
the blood were too low and/or a great deal of DNA was lost
during the extraction process. This concept is supported by
similar low detection results observed using T. brucei (TBR)
PCR and RIME LAMP tests specific for the multicopy and
highly sensitive subgenus Trypanozoon (34). Further studies
need to be carried out using only confirmed stage 1 patients to
elucidate the sensitivity of the TgsGP LAMP test versus other
molecular tests.
The application of nucleic acid-based tests in the diagnosis
of Gambian sleeping sickness has been limited in the areas of
endemicity, since most of the tests still require standardization
and clinical validation (8). Furthermore, they are laborious and
expensive and require elaborate visualization methods. In this
study, the potential usefulness of the TgsGP LAMP test was
demonstrated by its ease of applicability, rapidity, and higher
sensitivity than the classical PCR targeting the same gene (Ta-
ble 4). Moreover the ability of the test to detect parasite DNA
in CSF is expected to contribute to diagnosis of the late-stage
disease. Indeed, the staging of the late-stage HAT by the pres-
ence of trypanosomes in CSF and/or an elevated white blood
cell (WBC) count above 5 cells/cm2 is not reliable (11,) nor are
the existing CSF parasite detection methods sufficiently sensi-
tive (23). However, a positive LAMP CSF result needs to be
interpreted with caution, since it may not necessarily indicate
living trypanosomes in the CSF but rather their DNA. It has
been previously suggested that the presence of DNA in the
CSF may result from leakage of circulating DNA in the blood
through the blood brain barrier, or DNA can originate from
nonsurviving parasites as a consequence of the suboptimal CSF
survival environment (38). The issue of DNA rather than live
parasites complicating interpretation should be studied using a
primate model for HAT, which will elucidate the role of
TgsGP LAMP and other HAT LAMP tests in determining
cure. For now, LAMP results need to be interpreted in com-
parison to those of other tests and/or clinical symptoms.
Since the TgsGP LAMP test designed in this study is based
on the TgsGP gene, it does not detect T. b. gambiense group 2,
like TgsGP PCR. However, the vast majority of T. b. gambiense
patients across all foci have group 1 infections, and the overall
percentage of isolates from group 2 is so low as to be negligi-
ble, and only a few of them exist in laboratories. It is difficult to
get a specific marker for group 2, since it is heterogeneous and
genetically indistinguishable from T. brucei brucei. The lack of
a universal diagnostic marker for T. b. gambiense and the
reduced detection in blood affirms the need to continue eval-
uating other biomarkers. In practice, if the TgsGP LAMP test
(CSF) is to be introduced, it may need to be combined with a
test like CATT (blood) until the issues of LAMP sensitivity
using blood are resolved. The TgsGP LAMP test developed
here must be evaluated to investigate whether it can be used as
a xenomonitoring tool and in detection of the T. b. gambiense
parasite in suspected reservoir hosts (32).
The elimination of HAT as a public health problem in sub-
Saharan Africa is a realistic objective. However, this will rely in
part on the availability of affordable, sensitive, and field-appli-
cable diagnostic technologies. In summary, this work shows (i)
that the TgsGP LAMP is more sensitive than TgsGP PCR, (ii)
that the use of supernatant increases the test sensitivity by
10-fold, (iii) that the use of CSF increases the chance of par-
asite DNA detection for stage II disease compared to blood (or
its buffy coat from the same patient), and (iv) that the test is
robust and amplification can be achieved using a normal water
bath without compromising the test sensitivity. The LAMP test
designed in this work and other recent technologies, such as
the dipstick (10) and a sensitive semiquantitative card agglu-
tination test, Latex/IgM (21), offer new prospects for improved
detection of Gambian HAT. The next major step for the
TgsGP LAMP test will be focused on field evaluation with the
aim of generating data for development of a kit.
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